Filing Details

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

 

SCHEDULE 13D

(Rule 13d-101)

Information to be Included in Statements Filed Pursuant

to § 240.13d-1(a) and Amendments Thereto Filed

Pursuant to § 240.13d-2(a)

Under the Securities Exchange Act of 1934

(Amendment No. 4)

 

 

MERSANA THERAPEUTICS, INC.

(Name of Issuer)

Common Stock, $0.0001

par value per share

(Title of Class of Securities)

59045L106

(CUSIP Number)

Bain Capital Life Sciences Investors, LLC

200 Clarendon Street

Boston, MA 02116

617-516-2000

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

April 13, 2022

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.  ☐

 

 

Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See § 240.13d-7 for other parties to whom copies are to be sent.

 

 

The information required on the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (Act), or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

1		Names of reporting persons     Bain Capital Life Sciences Fund II, L.P.
2		Check the appropriate box if a member of a group   (a)  ☐        (b)  ☐
3		SEC use only
4		Source of funds     WC
5		Check if disclosure of legal proceedings is required pursuant to Item 2(d) or 2(e)     ☐
6		Citizenship or place of organization     Cayman Islands

Number of shares beneficially owned by each reporting person with:				7		Sole voting power     0 shares of Common Stock
				8		Shared voting power     3,294,423 shares of Common Stock
				9		Sole dispositive power     0 shares of Common Stock
				10		Shared dispositive power     3,294,423 shares of Common Stock

11		Aggregate amount beneficially owned by each reporting person     3,294,423 shares of Common Stock
12		Check if the aggregate amount in Row (11) excludes certain shares     ☐
13		Percent of class represented by amount in Row (11)     3.9%
14		Type of reporting person     PN

1		Names of reporting persons     BCIP Life Sciences Associates, LP
2		Check the appropriate box if a member of a group   (a)  ☐        (b)  ☐
3		SEC use only
4		Source of funds     WC
5		Check if disclosure of legal proceedings is required pursuant to Item 2(d) or 2(e)     ☐
6		Citizenship or place of organization     Delaware

Number of shares beneficially owned by each reporting person with:				7		Sole voting power     0 shares of Common Stock
				8		Shared voting power     401,244 shares of Common Stock
				9		Sole dispositive power     0 shares of Common Stock
				10		Shared dispositive power     401,244 shares of Common Stock

11		Aggregate amount beneficially owned by each reporting person     401,244 shares of Common Stock
12		Check if the aggregate amount in Row (11) excludes certain shares     ☐
13		Percent of class represented by amount in Row (11)     0.5%
14		Type of reporting person     PN

1		Names of reporting persons     BCLS II Investco, LP
2		Check the appropriate box if a member of a group   (a)  ☐        (b)  ☐
3		SEC use only
4		Source of funds     WC
5		Check if disclosure of legal proceedings is required pursuant to Item 2(d) or 2(e)     ☐
6		Citizenship or place of organization     Delaware

Number of shares beneficially owned by each reporting person with:				7		Sole voting power     0 shares of Common Stock
				8		Shared voting power     4,041,733 shares of Common Stock
				9		Sole dispositive power     0 shares of Common Stock
				10		Shared dispositive power     4,041,733 shares of Common Stock

11		Aggregate amount beneficially owned by each reporting person     4,041,733 shares of Common Stock
12		Check if the aggregate amount in Row (11) excludes certain shares     ☐
13		Percent of class represented by amount in Row (11)     4.8%
14		Type of reporting person     PN

This Amendment No. 4 to Schedule 13D relates to the Common Stock of Mersana Therapeutics, Inc. and amends the initial statement on Schedule 13D filed by the Reporting Persons on April 17, 2020, as amended by Amendment No. 1 filed on January 12, 2021, Amendment No. 2 filed on January 3, 2022 and Amendment No. 3 filed on February 8, 2022 (the Initial Statement and, as further amended by this Amendment No. 4, the Schedule 13D). Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Initial Statement.

Item 3. Source and Amount of Funds or Other Consideration

Item 3 of the Initial Statement is hereby amended and supplemented to add the following:

On April 12, 2022, BCLS II Investco purchased 598,086 shares of Common Stock at a purchase price of $4.1798 per share. On April 13, 2022, BCLS II Investco purchased an additional 617,284 shares of Common Stock at a purchase price of $4.05 per share. The shares of Common Stock were purchased through the Issuers ATM facility. Cowen and Company, LLC acted as sales agent for the ATM facility. BCLS II Investco used its own working capital to acquire the shares of Common Stock.

Item 5. Interest in Securities of the Issuer

Item 5 of the Initial Statement is hereby amended and restated as follows:

The information set forth in Items 2 and 3 and on the cover pages of this Schedule 13D is incorporated by reference in its entirety into this Item 5.

(a) (c) As of the date hereof, BCLS II holds 3,294,423 shares of Common Stock, representing approximately 3.9% of the outstanding shares of Common Stock, BCIPLS holds 401,244 shares of Common Stock, representing approximately 0.5% of the outstanding shares of Common Stock, and BCLS II Investco holds 4,041,733 shares of Common Stock, representing approximately 4.8% of the outstanding shares of Common Stock. As a result of the foregoing and the relationships described in Item 2(a) of this Schedule 13D, the Reporting Persons may be deemed to beneficially own in the aggregate 7,737,400 shares of Common Stock, representing approximately 9.1% of the outstanding shares of Common Stock. The percentage of the outstanding shares of Common Stock held by the Reporting Persons is based on (i) 83,389,806 shares of Common Stock outstanding as of February 25, 2022, as reported by the Issuer in its Annual Report on Form 10-K for the year ended December 31, 2021 and (ii) the issuance and sale to BCLS II Investco of an aggregate of 1,215,370 shares of Common Stock under the ATM facility.

(d) Except as otherwise described in this Item 5, no one other than the Reporting Persons has the right to receive, or the power to direct the receipt of, dividends from, or the proceeds from the sale of, any of the Common Stock beneficially owned by the Reporting Persons as described in this Item 5.

(e) Not applicable.

SIGNATURES

After reasonable inquiry and to the best of its knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

 

Dated: April 14, 2022				Bain Capital Life Sciences Fund II, L.P.
				By:		Bain Capital Life Sciences Investors II, LLC,
						its general partner
				By:		Bain Capital Life Sciences Investors, LLC,
						its manager
				By:		/s/ Andrew Hack
						Name: Andrew Hack
						Title: Managing Director
				BCIP Life Sciences Associates, LP
				By:		Boylston Coinvestors, LLC,
						its general partner
				By:		/s/ Andrew Hack
						Name: Andrew Hack
						Title: Authorized Signatory
				BCLS II Investco, LP
				By:		BCLS II Investco (GP), LLC,
						its general partner
				By:		Bain Capital Life Sciences Fund II, L.P.,
						its manager
				By:		Bain Capital Life Sciences Investors II, LLC,
						its general partner
				By:		Bain Capital Life Sciences Investors, LLC,
						its manager
				By:		/s/ Andrew Hack
						Name: Andrew Hack
						Title: Managing Director